Valuation: Healios K.K.

Market Cap 38.9B 247M 219M 205M 186M 352M 23.71B 355M 2.48B 959M 12.12B 926M 906M P/E 2026 *
-7.14x
P/E 2027 * -12.5x
Enterprise Value 38.64B 245M 218M 203M 185M 349M 23.55B 353M 2.46B 953M 12.04B 920M 900M EV / Sales 2026 *
76.5x
EV / Sales 2027 * 10.8x
Free-Float
79.1%
Yield 2026 *
-
Yield 2027 * -
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-13 Healios K.K. announced that it has received ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-29 Healios K.K. announced that it expects to receive ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
01-20 Healios K.K. Announces Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-20 Healios Submits Japan Trial Plan for Global Phase 3 ARDS Study MT
1 day-2.05%
1 week-1.03%
Current month-3.69%
1 month-2.05%
3 months+14.80%
6 months-25.07%
Current year+4.74%
1 week 271
Extreme 271
301
1 month 270
Extreme 270
313
Current year 208
Extreme 208
483
1 year 208
Extreme 208
531
3 years 114
Extreme 114
747
5 years 114
Extreme 114
1,974
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 01/03/2018
Director of Finance/CFO 49 16/07/2019
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 49 01/02/2012
Director/Board Member 49 01/03/2018
Director/Board Member 73 01/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.05%-1.03%-42.48%+28.70% 247M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.41%-0.63%+43.12%+118.55% 39.08B
Weighted average by Cap. +0.12%-0.84%+56.89%+138.19%

Financials

2026 *2027 *
Net sales 505M 3.2M 2.85M 2.66M 2.42M 4.57M 308M 4.61M 32.15M 12.46M 157M 12.03M 11.77M 3.74B 23.73M 21.08M 19.68M 17.93M 33.82M 2.28B 34.14M 238M 92.27M 1.17B 89.09M 87.15M
Net income -3.63B -23M -20.44M -19.07M -17.38M -32.79M -2.21B -33.09M -231M -89.44M -1.13B -86.35M -84.48M -1.81B -11.46M -10.18M -9.5M -8.66M -16.34M -1.1B -16.49M -115M -44.56M -563M -43.02M -42.09M
Net Debt -260M -1.65M -1.46M -1.37M -1.25M -2.35M -158M -2.37M -16.53M -6.41M -80.95M -6.18M -6.05M 1.46B 9.28M 8.24M 7.69M 7.01M 13.22M 892M 13.35M 93.09M 36.07M 456M 34.83M 34.07M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
02/10/26 ¥287.00 -2.05% 1,102,500
01/10/26 ¥293.00 -1.68% 1,330,600
30/09/26 ¥298.00 +8.76% 2,461,500
29/09/26 ¥274.00 -4.20% 1,796,200
28/09/26 ¥286.00 -1.38% 1,206,300
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
287.00JPY
Average target price
794.83JPY
Spread / Average Target
+176.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock